Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
AVI BioPharma develops therapeutic products for the treatment of life,threatening diseases using third,generation NeuGene® antisense drugs. AVI’s lead NeuGene antisense compound is designed to target cell proliferation disorders, including cardiovascular restenosis, cancer and polycystic kidney disease. In addition to targeting specific genes in the body, AVI’s antiviral program uses NeuGene antisense compounds to combat disease by targeting single,stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, Ebola virus and influenza A virus. AVI has introduced a NeuGene,based exon,skipping technology called ESPRIT therapy. ( www.avibio.com )
AVI BioPharma , Inc.
4575 SW Research Way Ste 200
Corvallis, Oregon 97333
USA
Tel: (503) 443-7000
Fax: (541) 754-3545